Kura Oncology Inc. | Ownership
Companies that own Kura Oncology Inc.
Ecor1 Capital LLC
3,904,675
10.28%
137,823
8.32%
06/30/2018
Fidelity Management & Research Co.
3,366,419
8.86%
-728,096
0.01%
06/30/2018
Great Point Partners LLC
2,627,110
6.92%
246,264
7.38%
06/30/2018
BVF Partners LP
2,057,346
5.42%
0
2.84%
07/09/2018
BlackRock Fund Advisors
1,873,466
4.93%
373,326
0%
06/30/2018
Victory Capital Management, Inc.
1,489,240
3.92%
1,489,240
0.06%
06/30/2018
The Vanguard Group, Inc.
1,376,422
3.63%
170,823
0%
06/30/2018
Eagle Asset Management, Inc.
1,367,135
3.6%
1,367,135
0.13%
06/30/2018
Partner Fund Management LP
1,097,383
2.89%
-253,197
0.39%
06/30/2018
SSgA Funds Management, Inc.
1,035,181
2.73%
256,297
0%
06/30/2018
| Address |
3033 Science Park Road
San Diego California 92121
United States
|
|
Employees
|
- |
| Website |
http://www.kuraoncology.com |
| Updated |
07/08/2019 |
| Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. |
